This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MGEN vs. OPGN, SKIN, LFCR, DRTS, DBVT, CDXS, CBIO, VNDA, VMD, and MREOShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include OpGen (OPGN), Beauty Health (SKIN), Lifecore Biomedical (LFCR), Alpha Tau Medical (DRTS), DBV Technologies (DBVT), Codexis (CDXS), Crescent Biopharma (CBIO), Vanda Pharmaceuticals (VNDA), Viemed Healthcare (VMD), and Mereo BioPharma Group (MREO). These companies are all part of the "medical" sector. Miragen Therapeutics vs. Its Competitors OpGen Beauty Health Lifecore Biomedical Alpha Tau Medical DBV Technologies Codexis Crescent Biopharma Vanda Pharmaceuticals Viemed Healthcare Mereo BioPharma Group OpGen (NASDAQ:OPGN) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Which has preferable valuation and earnings, OPGN or MGEN? OpGen has higher earnings, but lower revenue than Miragen Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpGen$2.67M0.00-$32.67MN/AN/AMiragen Therapeutics$4.46M16.27-$41.87M-$20.09-0.92 Which has more risk and volatility, OPGN or MGEN? OpGen has a beta of -1.77, suggesting that its share price is 277% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Does the media refer more to OPGN or MGEN? In the previous week, OpGen's average media sentiment score of 0.00 equaled Miragen Therapeutics'average media sentiment score. Company Overall Sentiment OpGen Neutral Miragen Therapeutics Neutral Do insiders and institutionals have more ownership in OPGN or MGEN? 2.7% of OpGen shares are owned by institutional investors. 43.8% of OpGen shares are owned by insiders. Comparatively, 1.1% of Miragen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is OPGN or MGEN more profitable? OpGen has a net margin of -1,140.36% compared to Miragen Therapeutics' net margin of -1,393.50%. OpGen's return on equity of 0.00% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OpGen-1,140.36% N/A -287.58% Miragen Therapeutics -1,393.50%-141.66%-88.74% SummaryOpGen beats Miragen Therapeutics on 5 of the 8 factors compared between the two stocks. Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.57M$1.23M$5.74B$9.77BDividend YieldN/AN/A4.40%4.08%P/E Ratio-1.74N/A30.4126.04Price / Sales16.271.83428.97104.72Price / CashN/AN/A25.7828.79Price / Book2.740.119.706.08Net Income-$41.87M-$22.69M$3.27B$265.64M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$18.57-3.4%N/A+27.7%$72.57M$4.46M-1.7445High Trading VolumeOPGNOpGenN/A$0.00flatN/A-100.0%$1K$2.67M0.00100SKINBeauty Health1.6157 of 5 stars$2.16-1.4%$2.63+21.5%+21.4%$277.75M$334.30M-7.711,030LFCRLifecore Biomedical0.7106 of 5 stars$7.25-2.0%$8.00+10.3%+26.5%$276.82M$128.87M-5.53690DRTSAlpha Tau Medical3.0136 of 5 stars$3.12-4.3%$9.00+188.5%+45.9%$276.51MN/A-6.5080Positive NewsDBVTDBV Technologies2.7732 of 5 stars$9.77-2.3%$14.75+51.0%+112.8%$273.90M$4.15M-2.0580Positive NewsGap UpCDXSCodexis3.4642 of 5 stars$2.87-4.3%$11.00+283.3%-12.1%$270.80M$57.16M-3.46250CBIOCrescent Biopharma3.78 of 5 stars$13.60-1.4%$25.50+87.5%N/A$269.59MN/A-0.3950News CoverageAnalyst ForecastVNDAVanda Pharmaceuticals4.311 of 5 stars$4.53-0.7%$16.50+264.2%-15.6%$269.45M$198.77M-4.01290VMDViemed HealthcareN/A$6.95+0.4%N/A-4.1%$268.40M$224.26M20.441,179MREOMereo BioPharma Group1.9088 of 5 stars$1.64-2.4%$7.20+339.0%-64.0%$267.12M$10M-23.4340Analyst Forecast Related Companies and Tools Related Companies OpGen Alternatives Beauty Health Alternatives Lifecore Biomedical Alternatives Alpha Tau Medical Alternatives DBV Technologies Alternatives Codexis Alternatives Crescent Biopharma Alternatives Vanda Pharmaceuticals Alternatives Viemed Healthcare Alternatives Mereo BioPharma Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGEN) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access